Safety and Efficacy of VB10.16 and Pembrolizumab in Patients with Head-Neck Squamous Cell Carcinoma

NCT06016920 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

51

Enrollment

INDUSTRY

Sponsor class

Conditions

HPV Positive Oropharyngeal Squamous Cell Carcinoma
HNSCC

Interventions

BIOLOGICAL: VB10.16
DRUG: Pembrolizumab

Sponsor

Nykode Therapeutics ASA

Collaborators

[object Object]